GlassScriptPhysician profile
Nan O Walicki
NPI 1871604173
$2,066.08
in general payments reported to CMS, 2019-2025
23 companies · $402 in 2025
The $402 reported for 2025 was more than what 90% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $571 · 2020: $205 · 2021: $148 · 2022: $100 · 2023: $211 · 2024: $429 · 2025: $402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,042.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,041.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $404.03 | 2019-2025 | Dyanavel Xr |
| Sanofi Pasteur INC. | $237.20 | 2019-2025 | |
| Corium, LLC | $221.49 | 2023-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $182.15 | 2021-2025 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Ironshore Pharmaceuticals INC. | $142.11 | 2019-2024 | |
| Seqirus USA INC | $120.46 | 2024-2025 | Flucelvax |
| Neos Therapeutics, LP | $115.62 | 2019-2024 | Adzenys Xr-Odt |
| Genentech USA, INC. | $86.25 | 2019-2022 | |
| Pfizer INC. | $78.67 | 2019-2024 | |
| Shire North American Group INC | $70.88 | 2019 | |
| Kaleo, INC. | $63.78 | 2019-2020 | |
| Cranial Technologies, INC | $58.78 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $55.55 | 2019-2020 | |
| Welch Allyn | $41.04 | 2021 | |
| Rhodes Pharmaceuticals L.P. | $32.84 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $31.12 | 2023 | Flumist Quadrivalent |
| Alk-Abello, INC | $26.78 | 2025 | Neffy |
| Verrica Pharmaceuticals INC. | $19.76 | 2024 | Ycanth |
| Sobi, INC | $19.66 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.83 | 2020 | |
| Phadia US INC. | $14.37 | 2019 | |
| Adlon Therapeutics L.P. | $14.04 | 2020 | |
| Mylan Pharmaceuticals INC. | $13.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nan Walicki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.